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Abstract
Background: Fever is a well-known side effect of misoprostol, but clinically difficult to distinguish from an intra
uterine infection. The aim of this study was to determine the incidence of fever in terminations of pregnancy (TOP)
using misoprostol and to evaluate fever as indication of intra uterine infection.
Methods: A retrospective cohort study was performed. Consecutive second trimester TOP with misoprostol
between January 2008 and October 2012 were selected. We included 403 cases and determined the incidence of
fever. To examine intra uterine infection as plausible cause of fever, pathological examination reports of placentas
were reviewed for signs of infections.
Results: The incidence of fever was 42%. Logistic regression showed a dose dependent association between
dosage misoprostol and degree of fever (OR 1.86; 95% CI: 1.3–2.7). There was no association between fever and
epidural analgesia. Fever has a sensitivity of 55% and a specificity of 58% as a marker of intra uterine infection.
The positive predictive value of fever for an intra uterine infection is 4% and the negative predictive value is 98%.
Conclusion: Administration of misoprostol for the indication TOP is strongly associated with fever during labor.
Fever is a poor predictor of intra uterine infection in the context of TOP.
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Background
Termination of pregnancy (TOP) in case of intra uterine
fetal death (IUFD) or in pregnancies complicated by
congenital abnormalities is a frequently practiced pro-
cedure worldwide [1]. Worldwide, every year 22% of all
pregnancies (46 million) result in an induced abortion;
this includes both medical and surgical methods [1, 2].
Most terminations of pregnancy are performed before
12 weeks of gestation and are mostly performed by dila-
tation and curettage. Yet approximately 10 to 15% are
performed in the second trimester, defined as 12 to
28 weeks of gestation, and are mostly conducted medic-
ally. These second trimester TOPs are responsible for
two-thirds of all major complications in TOPs, including
severe haemorrhage and infection [1, 3] In addition, the
number of second trimester TOPs has increased since
the introduction of prenatal screening programs follow-
ing an increase in detection rate and earlier detection of
fetal anomalies [1, 2].
The most efficient regimen for a medical TOP is a
combination of mifepristone, an antiprogesterone, and
vaginally administered misoprostol, a synthetic prosta-
glandin E1 analogue [4]. Misoprostol was originally
developed for prevention and treatment of peptic ulcer
disease. A side effect of misoprostol is uterine contractil-
ity and cervical ripening which has led to its off-label
use for TOP [1, 5]. Fever is a well-described side effect
of misoprostol [1, 3, 5]. The incidence of fever as a side
effect of misoprostol reportedly varies from 10 up to
50% [1, 5–11]. The majority of fever is temporary and
resolves spontaneously. However, clinically, fever as a
side effect of misoprostol and fever caused by intra
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uterine infection can be difficult to distinguish. An-
other explanation for the development of fever after
administration of misoprostol is that prostaglandin
interferes with the hypothalamus (where the body
temperature is regulated) by a shift in the temperature
set point, which results in a systemic response of in-
creased temperature [12].
Recent research showed that clinical signs of an infec-
tion are not accurate in the diagnosis intra uterine infec-
tion in term parturients [13]. The significance of fever as
an indicator of intra uterine infection in women under-
going TOP has never been addressed in literature. The
increasing incidence of epidural analgesia during labour,
which is also associated with fever, makes this distinction
even more difficult [14]. One of the consequences of
incorrectly interpreting fever as a sign of infection is the
unnecessary administration of antibiotics adding to the
growing problem of bacterial resistence [15].
Aim of the study
The primary aim of this study is to determine the inci-
dence and evaluate the test characteristics of fever in
second trimester TOP using misoprostol for the predic-
tion of intra uterine infection.
Methods
Study design
A retrospective descriptive study was performed at the VU
University Medical Center, Amsterdam, the Netherlands,
a tertiary academic center. All consecutive second trimes-
ter terminations of pregnancy (12–28 weeks gestation)
using misoprostol occurring between January 2008 and
October 2012 were selected.
Inclusion criteria were defined as a second trimester
TOP (gestational age between 12 and 28 weeks) by mi-
soprostol using the local second trimester regimen.
Exclusion took place for the following reasons: (1) fever
or antibiotic therapy before starting misoprostol or sus-
pected infection before induction, (2) incomplete med-
ical charts (e.g. no temperatures noted) or (3) protocol
violation in misoprostol dosage.
The VUMC second trimester protocol for TOP, which
is based on the national guidelines of the Dutch Society
of Obstetrics and Gynaecology consists of 200 mg mife-
pristone orally 36–48 h before starting misoprostol. The
national guidelines are based on guidelines by the Royal
College of Obstetricians and Gynaecogists and the
World Health Organisation. At the day of induction, a
start dose of 600 μg is administered vaginally, in the
posterior fornix, followed by 400 μg every 3 h, with a
maximum of 5 doses per day. Patient’s vital functions
are being measured at least every 8 h: temperature, heart
rate and blood pressure.
Fever was defined as a rectal temperature >37.8 °C
(100 °F). The following information was collected for all
women (with and without fever). Vital parameters, used
as indicators of shock, were listed: lowest systolic and
diastolic blood pressure (mmHg) and highest heart rate
(bpm). When antibiotics were administered, the initi-
ation time and duration of therapy were noted. Blood
samples and cultures are not drawn routinely, but when
fever is present it is at the clinicians discretion to decide
which diagnostics are being done. Infection parameters
in the blood such as C-reactive protein (CRP) and leuco-
cytes were noted. The normal range of CRP was esta-
blished as a value < 10 mg/L, the normal range of
leucocytes in pregnancy as 5.6–13.8*10^9/L [16, 17].
The number of patients with fever, total dose of miso-
prostol and induction-to-expulsion time were deter-
mined. To investigate an infection as a probable cause
for fever, results of blood, vagina or urine cultures were
reviewed. In addition, reports of pathological examin-
ation of the placentas from all women have been
reviewed for signs of infections. If a report mentioned
signs of infection, histologic placental material was re-
examined by an anatomical pathologist, specialized in
placental pathology (JPvdV).
The placentas with signs of infection were catego-
rized in stages of inflammatory response. Stage II or III
reaction are indicative of a clinical intra uterine infec-
tion [18].
Stage:
0. No sign of infection
I. Early: acute subchorionitis or chorionitis
II. Intermediate: acute chorioamnionitis






Due to the retrospective nature of this study ethical
approval was not required.
Legality
Legality of terminations of pregnancy has the same
principles as abortions for social indications in the
Netherlands. Termination of pregnancy, for either indi-
cation, is legal before 24 weeks of gestation taken into
consideration a 5 day-period of reflection. After
24 weeks TOP is only permitted in cases where fetal
malformation are incompatible with life or severe mor-
bidities are expected.
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Statistical analysis
Non-parametric tests were used because our data were
not normally distributed. Using presence of stage II or
III reaction as the gold standard for an intra uterine in-
fection, test characteristics of fever could be calculated.
The Mann-Whitney U-test was for continues variables.
We categorized gestational age (GA) (>98 days, 98–112
days, 112–126 days, 126–140 days, 140–154 days, 154–
168 days and >168 days) and the administered doses of
misoprostol (600 μgr, 600–1200 μgr, 1200–1800 μgr,
1800–2400 μgr, 2400–3000 μgr and ≥3000 μgr). The
Kruskal-Wallis-test was used to compare the differences
in mean highest temperature in categorized dose of mi-
soprostol and gestational age. We used the Chi-Square
test or Fisher’s exact test for categorical variables. To
control for the confounder epidural analgesia, a mul-
tiple logistic regression with the presence of fever as
dependent was performed. Determinants were presence
of epidural analgesia and required dose of misoprostol.
We expected a strong association between duration of
labor and required dosage of misoprostol. Pearson
correlation was calculated to verify this. Results are pre-
sented in Odds Ratio (OR) and 95% Confidence Interval
(CI). Tests were considered statistically significant when
p < 0.05. Statistical analysis was performed using SPSS
(SPSS inc., version 20, Chicago, USA).
Results
In the period January 2008 till October 2012, 458 termi-
nations of pregnancy took place. A total of 403 women
were included. Women were excluded for the following
reasons: (1) fever before induction of labor (n = 11), (2)
incomplete medical charts (n = 30) or (3) protocol viola-
tion of misoprostol dosage (n = 14).
Of all women, 168 (42%) developed fever. The major-
ity of these patients (71.5%) had a rectal temperature
between 38.0 and 38.9 °C. Most fever developed within
10 h after the start of induction and disappeared after
expulsion. Compared to those who did not develop fever,
women with fever more often were of advanced gesta-
tional age, more often were nulliparous, had a longer
induction-expulsion time, and a higher total dosage
misoprostol (Table 1).
Pathological examination of the placentas
In total, 298 out of 403 (74%) placenta reports could be
retrieved. In patients with fever 127 (76.0%) placentas
were sent for examination. In patients without fever 171
Table 1 Patient characteristics
Patients with fever (n = 168) Patients without fever (n = 235) P-value
Gestational age in days (Mean ± SD) 139 ± 58 121 ± 27 <0.001
Nulliparous, n (%) 63.1 39.1 <0.001
Induction-expulsion time, hours (Mean ± SD) 15 ± 14 8 ± 6 <0.001
Birth weight, grams (Mean ± SD) 365 ± 319 208 ± 227 <0.001
Total administered dose of misoprostol,μgr (Mean ± SD) 1946 ± 1101 1254 ± 611 <0.001
Total blood loss, mL (Mean ± SD) 313 ± 416 382 ± 444 0.397
Indications for TOP 0.10
Fetal anomaly, n (%) 154 (91.7%) 202 (85.9%)
IUFD, n (%) 11 (6.5%) 19 (8.1%)
Miscellaneous n (%) 3 (1.8%) 14 (6.0%)
Vital parameters (mean ± SD)
Systolic blood pressure, mmHg 109 ± 12 105 ± 12 <0.01
Diastolic blood pressure, mmHg 66 ± 10 65 ± 10 0.161
Heart rate, beats per minute 83 ± 13 76 ± 10 <0,001
CRP values n = 45 n = 5 0.21
Elevated CRP values, n (%) 14 (31%) 3 (60%)
Leukocyte values n = 45 n = 5 0.26
Elevated leukocyte values, n (%) 22 (49%) 3 (60%)
non parametric tests were used in case of not normally distributed data
Type of culture n Positive, n (%) Negative, n (%)
Blood 18 0 (0) 18 (100)
Vaginal 19 3 (16) 16 (84)
Urine 12 0 (0) 12 (100)
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(72.5%) placentas were sent for examination. In patients
with fever, 5 placentas (3%) showed a stage II or III reac-
tion, which is indicative for an intra uterine infection
[18]. In patients without fever, 4 patients (2%) were
found to have a stage II or III reaction. Table 2 shows
the characteristics of women in which the placenta
showed signs of stage II or III infection.
Test characteristics of fever
Using presence of stage II or III reaction as the gold
standard for an intra uterine infection, test characteris-
tics of fever were calculated. Table 3 shows the test char-
acteristics (sensitivity, specificity, positive predictive
value and negative predictive value), based on the group
for which revision of pathology reports was available.
Fever has a sensitivity of 55% and a specificity of 58%.
The positive predictive value for an infection is 4% and
the negative predictive value is 98%.
Dose response relation
The mean administered dose of misoprostol in the
group of patients with fever was significantly higher than
in the group without fever (Table 1). Fig. 1 shows the
increasing temperature and percentage of fever with
increasing dosage of misoprostol. Pearson correlation
showed a strong association (0.919; p < 0.001) between
required dose of misoprostol and duration of induction.
For analgesia during induction, 36.7% received epidural
analgesia. 61,5% of those patients had fever, which is
significantly higher than in the group without epidural
analgesia. However, binary logistic regression showed no
significant effect of epidural analgesia (OR 0.32; 95% CI:
0.07–1.37). The effect of misoprostol on the presence
of fever proved to be significant (OR 1.86; 95% CI:
1.3–2.7). The mean administered dose of misoprostol
was significant higher in the group with epidural analgesia
(p < 0.01).
Antibiotic therapy
In 31 (19%) of patients with fever antibiotic therapy was
started. Grade 2 or higher chorioamnionitis was found
in two of these patients. So in two out of 31 women an
intra uterine infection was found. In the first case, anti-
biotic therapy was started directly after expulsion of
the fetus because of smelly discharge. Vaginal culture
showed no growth of bacteria. The second case presented
with immature rupture of membranes. Antibiotic therapy
was started at the beginning of induction before fever
was noted. Vaginal swab also was negative.
Discussion
We found an incidence of 42% of fever in terminations
of pregnancy using misoprostol. Based on placenta path-
ology as the gold standard for defining intra uterine
infection, fever had a positive predictive value of 4% in
our study population, rendering it useless as a sign for
the presence of an intra uterine infection. Our results
show that in the majority of cases the presence of fever
appears to be a side effect of misoprostol rather than a
sign of an intra uterine infection. Furthermore a dose
response relation was found, which makes the evidence
of fever as a side effect of misoprostol stronger.
Fever is a well described side effect of misoprostol
[1, 3, 5]. The mechanism of fever after administration
of misoprostol, a Prostaglandin E1, has been inves-
tigated for the indication prevention of postpartum
Table 2 Characteristics of women with infected placentas








Leukocytes (*10^9/L) Culture EDA Duration of
labour
Indication
0 17 + 0 6800 III 39 13,8 10,8 V: neg Yes 71h30m Trisomy 21
0 17 + 5 1000 II 38,5 - - - No 05m45m IUFD
0 21 + 0 2200 II 38,4 - - - No 15h50m Increased nuchal
translucency
1 19 + 1 1000 II 37,9 - - - No 06h45m IUFD
3 24 + 1 1800 III 38,1 22 13,5 V/U: neg No 12h00m Immature rupture of
membranes
2 14 + 5 1000 III <37,8 - - - Yes 05h32m Immature rupture of
membranes
0 15 + 0 1000 II <37,8 - - - Yes 07h30m Hychroma colli
0 20 + 0 1000 II <37,8 - - - No 00h10m Immature rupture of
membranes
1 23 + 4 1000 III <37,8 21 15,6 - No 04h10m Immature rupture of
membranes
GA gestational age, CRP C-reactive protein, EDA epidural analgesia, IUFD intra uterine fetal death
Culture: v vaginal, u urine, Neg negative
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hemorrhage [12, 19]. Prostaglandins E-series are in-
volved in the endogenous origin of fever by interfering
with the hypothalamus, where body temperature is
regulated, inducing a shift in the hypothalamic set
point by interaction resulting in a systemic response.
Due to this response, heat-creating effects are initiated
to achieve increased temperature level [12]. On the
other hand, fever is known to be associated with the
presence of an infection. Infection is a serious mater-
nal complication resulting in 15% of maternal death
worldwide [20]. This underlines the importance of
discriminating the cause of fever; drug induced or
underlying intra uterine infection. The urge is for a
sensitive test during labor. Since pathological conform-
ation is the gold standard for intra uterine infection,
we used the diagnosis only to confirm after delivery
and to test its sensitivity. Table 1 describes the culture
results. Only three out of 19 vaginal cultures turned
out positive. One was positive for gardnerella vaginalis
and candida albicans, which are not a likely cause of
fever [21, 22]. The other showed positive for group B
streptococcus (GBS). In 19% of pregnant women, GBS
can be found in vaginal culture. Most of these women
are asymptomatic [23]. Furthermore placentas of both
patients with positive vaginal cultures did not show
signs of infection.
The strength of this study is that one specialized
pathologist reviewed all placentas. This ensures the
uniformity of the examination and minimized the risk
of intra observer variability. Furthermore all patients
received the same regimen of misoprostol. This in-
creases the comparability of the patients. A limitation
of this study is that it is retrospective. Therefore the
incidence of fever might be underreported; the
temperature was not measured every hour and occa-
sionally a peak temperature might have been missed.
However, we used strictly rectal temperatures for a
high uniformity in the measurements. Furthermore,
due to the retrospective nature of the study not all data
required was present. Preferably we would have cul-
tures, blood examination and placental examination
from all patients. A second limitation is that not all
placentas were investigated (n = 105). However the
amount of placentas investigated did not differ between
women with and without fever. Even if all placentas
not investigated would have showed signs of stage II or
III infection fever would have had a sensitivity of 43%
and a specificity of 58%. The positive predictive value
for an infection would have been 27% and the negative
predictive value 71%. So also in this hypothetical calcu-
lation fever is not an accurate predictor of an intra
uterine infection.
In the majority of the cases the presence of fever
seems to be a side effect and not a sign of an intra uter-
ine infection. There were no patients in septic shock or
critically ill in this study population. As in most cases
fever developed within 10 h after the start of induction
and disappeared after expulsion, it might be sufficient to
Fig. 1 Administered doses of misoprostol with corresponding proportions of fever and the mean highest temperature
Table 3 Test characteristics of fever
Infection + Infection - Total
Fever + 5 122 127 PPV: 4%
Fever - 4 167 171 NPV: 98%
Total 9 289 298
Sensitivity: 55% Specificity: 58%
+: present; -: absent; PPV positive predictive value, NPV negative
predictive value
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only administer antipyretic drugs such as paracetamol,
and IV-fluids. The use of antibiotics during termination
of pregnancy using misoprostol is therefore debatable.
Given the increased levels of antibiotic resistance
[14], it is recommendable to be cautious with initiat-
ing antibiotic therapy until other clinical signs of in-
fection are more likely. Future research should focus
on prospective data collection of women with a sec-
ond trimester TOP using misoprostol, with placental
histopathological examination of all placentas, blood
samples and cultures. Recent research has shown that
procalcitonin is a useful predictor for bacterial infec-
tion [24]. It could be interesting to investigate
whether procalcitonin can also be useful in the pre-
diction of intra uterine infection in patients with sec-
ond trimester TOP using misoprostol. Combining all
data might lead to development of a prediction model
for the presence of a intra uterine infection.
Conclusion
In conclusion administration of misoprostol for the indi-
cation TOP is highly associated with fever during labor,
but fever has no accurate test characteristics for the
presence of an intra uterine infection.
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